TPST stock icon

Tempest Therapeutics
TPST

$2.22
1.35%

Market Cap: 49.3M

 

About: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Employees: 17

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

74% more call options, than puts

Call options by funds: $740K | Put options by funds: $425K

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

3.1% less ownership

Funds ownership: 11.5% [Q4 2023] → 8.4% (-3.1%) [Q1 2024]

6% less funds holding

Funds holding: 32 [Q4 2023] → 30 (-2) [Q1 2024]

25% less capital invested

Capital invested by funds: $9.74M [Q4 2023] → $7.29M (-$2.45M) [Q1 2024]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
260%
upside
Avg. target
$32
1,321%
upside
High target
$47
2,017%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Edward Tenthoff
260%upside
$8
Overweight
Reiterated
21 Jun 2024
HC Wainwright & Co.
Joseph Pantginis
2,017%upside
$47
Buy
Reiterated
20 Jun 2024
HC Wainwright & Co.
Joseph Pantginis
2,017%upside
$47
Buy
Reiterated
13 May 2024
HC Wainwright & Co.
Joseph Pantginis
2,017%upside
$47
Buy
Reiterated
10 May 2024
HC Wainwright & Co.
Joseph Pantginis
2,017%upside
$47
Buy
Reiterated
20 Mar 2024

Financial journalist opinion

Based on 3 articles about TPST published over the past 30 days